DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
1-Year Return
13.6%
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.13B
AUM Growth
-$216M
(-6.5%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-12.65%
Top 10 Holdings %
Top 10 Hldgs %
41.39%
Holding
77
New
10
Increased
20
Reduced
24
Closed
8
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$78.4M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$54.8M |
| 3 |
Immunovant
IMVT
|
$41.7M |
| 4 |
Guardant Health
GH
|
$34.4M |
| 5 |
Kura Oncology
KURA
|
$30.8M |
Top Sells
| 1 |
Amgen
AMGN
|
$180M |
| 2 |
Insmed
INSM
|
$134M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$122M |
| 4 |
Travere Therapeutics
TVTX
|
$95.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$89.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
26
Abivax
ABVX
$6.47B
| $41.2M | 1.31% |
3,579,209
-600,554
| -14% | -$6.92M |
|
27
TG Therapeutics
TGTX
$5.06B
| $40.3M | 1.28% |
1,725,000
-1,145,131
| -40% | -$26.8M |
|
28
MindMed
MNMD
$702M
| $40.2M | 1.28% |
7,065,099
+961,282
| +16% | +$5.47M |
|
|
29
Kura Oncology
KURA
$706M
| $38.4M | 1.22% |
1,963,505
+1,578,749
| +410% | +$30.8M |
|
30
Geron
GERN
$880M
| $34.4M | 1.09% |
7,575,049
-5,424,951
| -42% | -$24.6M |
|
31
Cytokinetics
CYTK
$5.95B
| $33.3M | 1.05% |
629,906
+497,411
| +375% | +$26.3M |
|
|
ORKA
32
Oruka Therapeutics, Inc. Common Stock
ORKA
$561M
| $30.3M | 0.96% |
+1,235,187
| New | +$30.3M |
|
33
ANI Pharmaceuticals
ANIP
$2.08B
| $30.1M | 0.96% |
504,828
+38,739
| +8% | +$2.31M |
|
34
Spyre Therapeutics
SYRE
$1.03B
| $29.4M | 0.93% |
1,000,000
-756,667
| -43% | -$22.3M |
|
35
Edgewise Therapeutics
EWTX
$1.54B
| $29.4M | 0.93% |
1,100,536
+914,150
| +490% | +$24.4M |
|
36
Kymera Therapeutics
KYMR
$3.02B
| $28.4M | 0.9% |
600,326
-899,674
| -60% | -$42.6M |
|
37
Korro Bio
KRRO
$264M
| $28.4M | 0.9% |
850,000
+79,355
| +10% | +$2.65M |
|
38
Avidity Biosciences
RNA
$6.24B
| $21.8M | 0.69% |
+475,000
| New | +$21.8M |
|
|
CNTA
39
Centessa Pharmaceuticals
CNTA
$2.12B
| $21.6M | 0.68% |
+1,350,000
| New | +$21.6M |
|
40
Alector
ALEC
$285M
| $21.6M | 0.68% |
4,631,998
| – | – |
|
41
Nektar Therapeutics
NKTR
$684M
| $20.7M | 0.66% |
1,061,510
-130,190
| -11% | -$2.54M |
|
42
89bio
ETNB
$1.28B
| $20.5M | 0.65% |
2,766,512
+472,501
| +21% | +$3.5M |
|
|
BCAX
43
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $20.3M | 0.64% |
+796,852
| New | +$20.3M |
|
44
Akero Therapeutics
AKRO
$3.52B
| $19.8M | 0.63% |
+689,784
| New | +$19.8M |
|
45
Fate Therapeutics
FATE
$112M
| $19.5M | 0.62% |
5,572,607
| – | – |
|
|
SLN
46
Silence Therapeutics
SLN
$247M
| $18.2M | 0.58% |
1,000,000
-359,745
| -26% | -$6.54M |
|
47
enGene Holdings
ENGN
$256M
| $17.2M | 0.55% |
2,607,633
+357,633
| +16% | +$2.36M |
|
48
Editas Medicine
EDIT
$227M
| $16.7M | 0.53% |
4,900,334
-1,099,666
| -18% | -$3.75M |
|
49
Xencor
XNCR
$597M
| $16.1M | 0.51% |
+800,000
| New | +$16.1M |
|
50
Pyxis Oncology
PYXS
$99.8M
| $15.4M | 0.49% |
4,184,100
| – | – |
|